Save

ABTECT - Maintenance

PHASE3RECRUITING

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i. e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors\].

This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106.

Simpliy with AI

Study details:

All eligible subjects who have completed either one of the induction studies above mentioned, will be given the opportunity to take part in the present ABX464-107 study which consists of 2 treatment phases. This study consists of a 44-week maintenance treatment phase (Part 1 and Part 2), followed by a 4-year Long Term Extension (LTE) treatment phase and a 28-days follow-up period consisting in the End of Study (EOS) visit. The maintenance phase is a 44-week double blind, placebo-controlled, phase.

Subjects who are clinical responders after 8 weeks induction will be randomized to Part 1, and those who are non-clinical responders will be randomized to Part 2. At the end of the 44-week maintenance phase, subjects will continue their allocated treatment until the maintenance phase is unblinded. Once the study is unblinded, all subjects receiving obefazimod will continue their allocated treatment.

Subjects receiving placebo will be allocated to obefazimod 25 mg or can terminate the study.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Subjects must have completed the induction treatment study (ABX464-105 or ABX464-106), and patients' clinical response status must be available.

Subjects with a valid endoscopy performed at the end of the induction study and results from central reader available at Day 1.

Subjects must understand, sign and date the written voluntary informed consent form at the visit prior to any protocol-specific procedures. For under-aged subjects, national requirements regarding consent should also be met.

Women of childbearing potential (WOCBP) subjects and male subjects with WOCBP partner must agree to comply with contraception requirements as described in Section 4.4. (Contraception) of the protocol.

Subjects must be able and willing to comply with study visits and procedures as per protocol.

Subjects should be affiliated to a health insurance policy whenever required by a participating country or state.

Subject must have completed the maintenance phase.

Investigator and subject must assess and agree that the subject has received, and will continue to receive benefit from being in the study.

Exclusion criteria

Subjects who permanently discontinued the study treatment during the induction study (either ABX464-105 or ABX464-106).

Subjects who have developed any major illness/condition (eg. primary sclerosis cholangitis, Crohn's disease, colectomy, diverting ileostomy, colon cancer or colonic adenomas [low or high grade dysplasia]).

Subjects with evidence of an unstable clinical condition (eg. toxic megacolon, fulminant colitis, bowel perforation, uncontrolled ischemic disease, congestive heart failure with NYHA class 3 or 4 symptoms) during the induction study that, in the investigator's judgment, will substantially increase the risk to the subject if he or she participates in the study.

Subjects who plan to participate in other investigational studies during the maintenance study.

Male or female planning a pregnancy, or pregnant female subjects.

Introduction during induction study of prohibited medications, dosages, surgical or non-medicinal procedures indicated for UC (except antidiarrheals and motility agents for acute diarrhea).

Any changes in the laboratory values during the induction period that could jeopardize subject's safety in the opinion of the investigator. If any doubts, the investigator should contact the sponsor study medical monitor.

Subject who is planning to receive live vaccine during the study.

Subjects committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.

Subject continues to satisfy exclusion criteria listed above for the maintenance phase.

Introduction during maintenance phase of prohibited medications, dosages, surgical or non-medicinal procedures indicated for UC (except antidiarrheals and motility agents for acute diarrhea).

Simplify with AI

Eligibility

Age eligible for study : 16 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2023-01-16

Primary completion: 2026-01-01

Study completion finish: 2030-01-01

Study type

TREATMENT

Phase

PHASE3

Trial ID

NCT05535946

Intervention or treatment

DRUG: ABX464

DRUG: Placebo

Conditions

• Ulcerative Colitis

Condition: Ulcerative Colitis
DRUG: ABX464 and other drugs
Blacktown, New South Wales, Australia and more
Sponsor: Abivax S.A.

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Blacktown Hospital

Research sites nearby

Select from list below to view details:

Blacktown Hospital
Blacktown, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Coral Sea Clinical Research Institute
North Mackay, Queensland, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
PLACEBO_COMPARATOR: ABX464 50mg - Responder subjects at the end of induction Subjects will be orally dosed during 44 weeks	DRUG: ABX464 Administered once daily, preferably in the morning, with food
PLACEBO_COMPARATOR: ABX464 25mg - Responder subjects at the end of induction Subjects will be orally dosed during 44 weeks	DRUG: ABX464 Administered once daily, preferably in the morning, with food
PLACEBO_COMPARATOR: Placebo - Responder subjects at the end of induction Subjects will be orally dosed during 44 weeks	DRUG: Placebo Administered once daily, preferably in the morning, with food
EXPERIMENTAL: ABX464 50mg - Non responder subjects at the end of induction Subjects will be orally dosed during 44 weeks	DRUG: ABX464 Administered once daily, preferably in the morning, with food
EXPERIMENTAL: ABX464 25mg - Non responder subjects at the end of induction Subjects will be orally dosed during 44 weeks	DRUG: ABX464 Administered once daily, preferably in the morning, with food
EXPERIMENTAL: Long Term Extension At the end of the maintenance phase (week 44), subjects can continue their allocated treatment for up to 4 years. Once the maintenance phase is unblinded, subjects receiving placebo in the maintenance phase will be allocated to obefazimod 25 mg or can terminate the study.	DRUG: ABX464 Administered once daily, preferably in the morning, with food

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Rate of subjects in clinical remission at Week 44	The Part 1 primary objective is to compare the efficacy of ABX464 versus placebo on the proportion of subjects in clinical remission \[SFS = 0 or 1, RBS = 0 and endoscopy sub-score = 0 or 1\] at Week 44.	Week 44
Number and percentage of all treatment-emergent adverse events (TEAEs)	The Part 2 primary objective is safety	Week 44
Number and percentage of all serious adverse events (SAEs)	The Part 2 primary objective is safety	Week 44
Number and percentage of all causally related TEAEs/SAEs	The Part 2 primary objective is safety	Week 44

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Proportion of subjects with endoscopic improvement at Week 44	To compare the efficacy of ABX464 versus placebo on endoscopic improvement (Mayo Endoscopic Subscore (MES) = 0 or 1) at Week 44	Week 44
Proportion of subjects with corticosteroid-free clinical remission	To compare the efficacy of ABX464 versus placebo on corticosteroid-free clinical remission (clinical remission at Week 44 and corticosteroid free for at least 12 weeks prior to Week 44 in the subpopulation with corticosteroids at maintenance study entry)	Week 44
Proportion of subjects with sustained clinical remission at Week 44	To compare the efficacy of ABX464 versus placebo to sustain clinical remission at Week 44	Week 44
Proportion of subjects with HEMI per Geboes scoring at Week 44	To evaluate the efficacy of ABX464 on histologic-endoscopic mucosal improvement (HEMI) versus placebo at Week 44	Week 44
Proportion of subjects with endoscopic remission at Week 44	To compare the efficacy of ABX464 versus placebo on endoscopic remission (MES = 0) at Week 44	Week 44
LTE Phase - Proportion of subjects in clinical remission at Year 1	To evaluate the efficacy of obefazimod on clinical remission \[SFS = 0 or 1, RBS = 0 and endoscopy sub-score = 0 or 1\] at Year 1	LTE Year 1
LTE Phase - Proportion of subjects in clinical remission at Year 4	To evaluate the efficacy of obefazimod on clinical remission \[SFS = 0 or 1, RBS = 0 and endoscopy sub-score = 0 or 1\] at Year 4	LTE Year 4
LTE Phase - Proportion of subjects with corticosteroid-free clinical remission in the subpopulation with corticosteroids at maintenance study entry	To evaluate the efficacy of obefazimod on CS-free clinical remission (clinical remission at Year 1 and corticosteroid free for at least 12 weeks prior to Year 1 in the subpopulation with corticosteroids at maintenance study entry)	LTE Year 1
LTE Phase - Proportion of subjects with corticosteroid-free clinical remission in the subpopulation with corticosteroids at maintenance study entry)	To evaluate the efficacy of obefazimod on CS-free clinical remission (clinical remission at Year 4 and corticosteroid free for at least 12 weeks prior to Year 4 in the subpopulation with corticosteroids at maintenance study entry)	LTE Year 4
LTE Phase - Proportion of subjects with endoscopic improvement at LTE Year 1	To evaluate the efficacy of obefazimod on endoscopic improvement (Mayo Endoscopic Subscore (MES) = 0 or 1)	LTE Year 1
LTE Phase - Proportion of subjects with endoscopic improvement at LTE Year 4	To evaluate the efficacy of obefazimod on endoscopic improvement (Mayo Endoscopic Subscore (MES) = 0 or 1)	LTE Year 4
LTE Phase - Proportion of subjects with endoscopic remission at LTE year 1	To evaluate the efficacy of obefazimod on endoscopic remission ((Mayo Endoscopic Subscore (MES) = 0)	LTE year 1
LTE Phase - Proportion of subjects with endoscopic remission at LTE year 4	To evaluate the efficacy of obefazimod on endoscopic remission (Mayo Endoscopic Subscore (MES) = 0)	LTE year 4
LTE Phase - Proportion of subjects with CS-free symptomatic remission by visit	To evaluate the efficacy of obefazimod on CS-free symptomatic remission (symptomatic remission (SFS = 0 or 1 and RBS = 0) and corticosteroid free for at least 12 weeks prior to Week 44 in the subpopulation with corticosteroids at maintenance study entry) by visit (every 3-month)	4 years
LTE Phase - Proportion of subjects with HEMI per Geboes scoring at LTE Year 1	To evaluate the efficacy of obefazimod on histologic endoscopic mucosal improvement (HEMI) per Geboes scoring	LTE Year 1
LTE Phase - Proportion of subjects with HEMI per Geboes scoring at LTE Year 4	To evaluate the efficacy of obefazimod on histologic endoscopic mucosal improvement (HEMI) per Geboes scoring	LTE Year 4
LTE Phase - Proportion of subjects with HEMR per Geboes scoring at LTE Year 1	To evaluate the efficacy of obefazimod on histologic endoscopic mucosal remission (HEMR) versus placebo	LTE Year 1
LTE Phase - Proportion of subjects with HEMR per Geboes scoring at LTE Year 4	To evaluate the efficacy of obefazimod on histologic endoscopic mucosal remission (HEMR) versus placebo	LTE Year 4
LTE Phase - Proportion of subjects with sustained clinical remission at LTE Year 1, in the sub-population of subjects with clinical remission at Week 44	To evaluate the efficacy of obefazimod on sustained clinical remission Sustained clinical remission for the LTE is defined as clinical remission assessed at an endoscopy visit during the LTE in the sub-population of subjects in clinical remission at Week 44.	LTE Year 1
LTE Phase - Proportion of subjects with sustained clinical remission at LTE year 4, in the sub-population of subjects with clinical remission at Week 44	To evaluate the efficacy of obefazimod on sustained clinical remission Sustained clinical remission for the LTE is defined as clinical remission assessed at an endoscopy visit during the LTE in the sub-population of subjects in clinical remission at Week 44.	LTE year 4
LTE Phase - Proportion of subjects with sustained endoscopic improvement at LTE Year 1, in the sub-population of subjects with endoscopic improvement at Week 44	To evaluate the efficacy of obefazimod on sustained endoscopic improvement	LTE Year 1
LTE Phase - Proportion of subjects with sustained endoscopic improvement at LTE Year 4, in the sub-population of subjects with endoscopic improvement at Week 44	To evaluate the efficacy of obefazimod on sustained endoscopic improvement	LTE year 4
LTE Phase - Proportion of subjects with symptomatic remission by visit	To evaluate the efficacy of obefazimod on symptomatic remission (SFS = 0 or 1 and RBS = 0) by visit (every 3-month)	4 years
LTE Phase - Proportion of subjects with sustained symptomatic remission by visit	To evaluate the efficacy of obefazimod on sustained symptomatic remission (SFS = 0 or 1 and RBS = 0) by visit (every 3-month), in the sub-population of subjects with symptomatic remission at Week 44	4 years
LTE Phase - Proportion of subjects with CS-free clinical remission at LTE Year 1	To evaluate the efficacy of obefazimod on CS-free clinical remission (clinical remission at Year 1 and CS-free for at least 12 weeks immediately prior to Year 1)	LTE Year 1
LTE Phase - Proportion of subjects with CS-free clinical remission at LTE Year 4	To evaluate the efficacy of obefazimod on CS-free clinical remission (clinical remission at Year 4 and CS-free for at least 12 weeks immediately prior to Year 4)	LTE Year 4

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: ABTECT - Maintenance